Sign inJoin waitlistJoin the waitlist

Caroline Nebhan

Physician · Intermountain Health

Credentials: · · · · · ·

History

Intermountain Health
2022–Present

Vanderbilt University Medical Center
2020–2022
Internal Medicine
Vanderbilt University Medical Center
2016–2018
Vanderbilt University School of Medicine
2012–2016

Research

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Cancer Discovery · 2014 · 1,861 citations
Immune-checkpoint inhibitors: long-term implications of toxicity
Review · Nature Reviews Clinical Oncology · 2022 · 811 citations
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
Cancer Discovery · 2012 · 597 citations

Douglas Johnson
17 papers
Abdul Naqash
7 papers
AS
Anwaar Saeed
6 papers
William Pao
5 papers
Amin Nassar
4 papers · 2 as a fellow
Maluki Radford
4 papers · 3 as a resident
Thomas Marron
4 papers
Yinghong Wang
4 papers
Chul Kim
3 papers
Dwight Owen
3 papers
Michael Davies
3 papers
Neha Debnath
3 papers · 3 as a resident

Grants

Investigating Concurrent Ras-Pathway Inhibition to Optimize Response to Anti-PD-1 Therapy in NRAS-Mutant Melanoma
National Cancer Institute · F32
Contact PI · $129.6K · Vanderbilt University Medical Center
2020–2022
The Role of NF2 in Acquired Resistance to Targeted EGFR Inhibition in Lung Cancer
National Cancer Institute · F30
Contact PI · $128.8K · Vanderbilt University
2013–2017

Clinical trials

A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Site PI · Recruiting · Phase 1
NextCure, Inc.
2025–2026
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Site PI · Recruiting · Phase 1
NiKang Therapeutics, Inc.
2024–2029
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Site PI · Recruiting · Phase 3
Replimune, Inc.
2024–2031